S&P 500   5,254.35 (+0.11%)
DOW   39,807.37 (+0.12%)
QQQ   443.97 (-0.19%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.05%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
S&P 500   5,254.35 (+0.11%)
DOW   39,807.37 (+0.12%)
QQQ   443.97 (-0.19%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.05%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
S&P 500   5,254.35 (+0.11%)
DOW   39,807.37 (+0.12%)
QQQ   443.97 (-0.19%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.05%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
S&P 500   5,254.35 (+0.11%)
DOW   39,807.37 (+0.12%)
QQQ   443.97 (-0.19%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.05%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)

Intra-Cellular Therapies (ITCI) Stock Price, News & Analysis

$69.20
-0.52 (-0.75%)
(As of 04:00 PM ET)
Today's Range
$68.14
$70.00
50-Day Range
$64.37
$75.65
52-Week Range
$45.50
$76.11
Volume
878,630 shs
Average Volume
789,471 shs
Market Capitalization
$6.70 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$81.42

Intra-Cellular Therapies MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.90 Rating Score
Upside/​Downside
18.8% Upside
$81.42 Price Target
Short Interest
Healthy
3.42% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.23
Upright™ Environmental Score
News Sentiment
1.40mentions of Intra-Cellular Therapies in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$28.60 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.65) to $0.93 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.63 out of 5 stars

Medical Sector

71st out of 939 stocks

Pharmaceutical Preparations Industry

27th out of 433 stocks

ITCI stock logo

About Intra-Cellular Therapies Stock (NASDAQ:ITCI)

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

ITCI Stock Price History

ITCI Stock News Headlines

AI to Meet the Same Fate as EVs?
When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11…
AI to Meet the Same Fate as EVs?
When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11…
ITCI Apr 2024 90.000 call
ITCI Aug 2024 50.000 call
See More Headlines
Receive ITCI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Intra-Cellular Therapies and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/22/2024
Today
3/28/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ITCI
Employees
610
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$81.42
High Stock Price Target
$101.00
Low Stock Price Target
$62.00
Potential Upside/Downside
+18.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.90
Research Coverage
10 Analysts

Profitability

Net Income
$-139,670,000.00
Pretax Margin
-29.94%

Debt

Sales & Book Value

Annual Sales
$464.37 million
Book Value
$6.15 per share

Miscellaneous

Free Float
93,516,000
Market Cap
$6.68 billion
Optionable
Optionable
Beta
1.02
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives


ITCI Stock Analysis - Frequently Asked Questions

Should I buy or sell Intra-Cellular Therapies stock right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Intra-Cellular Therapies in the last year. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ITCI shares.
View ITCI analyst ratings
or view top-rated stocks.

What is Intra-Cellular Therapies' stock price target for 2024?

10 equities research analysts have issued 1 year price targets for Intra-Cellular Therapies' shares. Their ITCI share price targets range from $62.00 to $101.00. On average, they anticipate the company's stock price to reach $81.42 in the next year. This suggests a possible upside of 18.8% from the stock's current price.
View analysts price targets for ITCI
or view top-rated stocks among Wall Street analysts.

How have ITCI shares performed in 2024?

Intra-Cellular Therapies' stock was trading at $71.62 on January 1st, 2024. Since then, ITCI shares have decreased by 4.3% and is now trading at $68.51.
View the best growth stocks for 2024 here
.

Are investors shorting Intra-Cellular Therapies?

Intra-Cellular Therapies saw a decrease in short interest in March. As of March 15th, there was short interest totaling 3,310,000 shares, a decrease of 10.5% from the February 29th total of 3,700,000 shares. Based on an average daily trading volume, of 798,300 shares, the short-interest ratio is presently 4.1 days.
View Intra-Cellular Therapies' Short Interest
.

When is Intra-Cellular Therapies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our ITCI earnings forecast
.

How were Intra-Cellular Therapies' earnings last quarter?

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) issued its quarterly earnings results on Thursday, February, 22nd. The biopharmaceutical company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.44) by $0.14. The biopharmaceutical company had revenue of $132.10 million for the quarter, compared to analyst estimates of $135.97 million. Intra-Cellular Therapies had a negative trailing twelve-month return on equity of 23.02% and a negative net margin of 30.08%. The company's quarterly revenue was up 50.3% compared to the same quarter last year. During the same quarter last year, the company posted ($0.45) earnings per share.

What other stocks do shareholders of Intra-Cellular Therapies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Intra-Cellular Therapies investors own include Sorrento Therapeutics (SRNE), Amarin (AMRN), Gilead Sciences (GILD), CRISPR Therapeutics (CRSP), Synergy Pharmaceuticals (SGYP), Myovant Sciences (MYOV), Novavax (NVAX), Pfizer (PFE), AbbVie (ABBV) and Clovis Oncology (CLVS).

Who are Intra-Cellular Therapies' major shareholders?

Intra-Cellular Therapies' stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (9.45%), Vanguard Group Inc. (9.39%), Wasatch Advisors LP (3.77%), Bellevue Group AG (3.19%), Avoro Capital Advisors LLC (2.34%) and Franklin Resources Inc. (1.85%). Insiders that own company stock include Christopher D Alafi, Christopher D Alafi, Joel S Marcus, Lawrence J Hineline, Lawrence J Hineline, Mark Neumann, Michael Halstead, Nostrand Robert L Van, Rory B Riggs, Sharon Mates, Suresh K Durgam and Suresh K Durgam.
View institutional ownership trends
.

How do I buy shares of Intra-Cellular Therapies?

Shares of ITCI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ITCI) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners